Focus on biosimilar etanercept - bioequivalence and interchangeability

about

Focus on biosimilar etanercept - bioequivalence and interchangeability

Item

http://www.wikidata.org/entity/Q57210818

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Focus on biosimilar etanercept - bioequivalence and interchangeability

@en

Focus on biosimilar etanercept - bioequivalence and interchangeability

@nl

type

Item

label

Focus on biosimilar etanercept - bioequivalence and interchangeability

@en

Focus on biosimilar etanercept - bioequivalence and interchangeability

@nl

prefLabel

Focus on biosimilar etanercept - bioequivalence and interchangeability

@en

Focus on biosimilar etanercept - bioequivalence and interchangeability

@nl

P1476

Focus on biosimilar etanercept - bioequivalence and interchangeability

@en

P2093

Fabrizio Cantini

http://www.w3.org/2001/XMLSchema#string

Maurizio Benucci

http://www.w3.org/2001/XMLSchema#string

P2860

Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study.

The nocebo effect of drugs.

Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe.

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.

GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.

Etanercept: a review of its use in autoimmune inflammatory diseases.

LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects.

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany.

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4.

P304

87-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.S126854

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30214149

http://www.w3.org/2001/XMLSchema#string

P921

gastroenterology

Infections

P932

6121755

http://www.w3.org/2001/XMLSchema#string